Impact Of Buntanetap Trial Results On Annovis Bio Stock And Future Prospects [Seeking Alpha]
Annovis Bio, Inc. (ANVS)
Company Research
Source: Seeking Alpha
Their pipeline includes Buntanetap/ANVS 402 for AD, PD, and Lewy Body Dementia, as well as other promising drugs for traumatic brain injuries and stroke. The recent volatility and drop in ANVS stock following mixed clinical trial results present potential risks, but there are still positive catalysts in the near term. Annovis Bio is preparing for Phase 3 trials in Alzheimer's, emphasizing the need for further study despite the mixed outcomes of earlier phases. I rate Annovis Bio a 'hold' due to promising yet mixed clinical results and potential upcoming catalysts that could influence the stock's recovery. Annovis Bio, Inc. ( NYSE: ANVS ) is a clinical-stage pharmaceutical company specializing in the development of treatments for neurodegenerative diseases, such as Alzheimer's [AD] and Parkinson's [PD]. ANVS's innovative approach focuses on disrupting neurotoxic proteins, which impair the axonal transport of critical Recommended For You Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of InvestorsBusiness Wire
- Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of InvestorsBusiness Wire
- The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of InvestorsBusiness Wire
- Annovis Bio, Inc. (NYSE: ANVS) had its price target lowered by analysts at HC Wainwright from $30.00 to $23.00. They now have a "buy" rating on the stock.MarketBeat
- Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
ANVS
Earnings
- 5/10/24 - Beat
ANVS
Sec Filings
- 5/13/24 - Form 8-K
- 5/10/24 - Form 10-Q
- 5/9/24 - Form 8-K
- ANVS's page on the SEC website